The Coriell Personalized Medicine Collaborative® (CPMC®) is a research study that employs an evidence-based approach to determine the utility of using personal genome information in health management and clinical decision-making. In addition, the structure of the CPMC study has allowed Coriell to build a cohort with rich genotypic and phenotypic data with which to discover genetic variation that affects drug toxicity and efficacy, as well as to discover presently unknown gene variants that elevate a person’s risk of complex diseases.
One of the many unique facets of the CPMC research study is its collaborative design, which brings together volunteer study participants, medical professionals, scientists, ethicists, genetic counselors, pharmacists, information technologists, and hospital partners. The CPMC provides an ideal environment in which to study the implementation of personalized medicine. This approach has allowed us to adapt and successfully implement the CPMC in diverse settings and with various partners including Ohio State University Medical Center, University of Pennsylvania, Boston University, Stanford University, and others.
The combination of our unique study design and our focus on education, ethical conduct, and scientific validity has garnered much praise: Nature magazine described the study as “leading by example,” and MIT Technology Review placed the CPMC on its 2010 “Top 10 Research Projects to Watch” list.
How Does the CPMC Work?
CPMC research study participants submit a saliva sample for genome analysis and answer online health questionnaires about lifestyle, medical and family history. In return, participants receive personalized risk assessments for potentially actionable health conditions – conditions where risk can be reduced by individual action (behavior or lifestyle) or by medical action (screening, preventive treatment, or early intervention) – and for responses to commonly prescribed medications in the form of gene-drug pairs. The CPMC has board-certified genetic counselors and a network of licensed pharmacists that are available to speak with participants about the genetic information they may learn as a result of being in the study. Participants are asked to complete periodic follow-up surveys to determine whether receipt of this information influenced their personal health decisions.
To decide which conditions and gene-drug pairs are potentially actionable, the CPMC research study engages two independent, expert advisory boards: the Informed Cohort Oversight Board (ICOB) and the Pharmacogenomics Advisory Group (PAG).
Visit our CPMC web portal for more information: www.cpmc.coriell.org